BerGenBio presents updated phase 2 NSCLC clinical and translational data for bemcentinib in combination with KEYTRUDA®
· BerGenBio’s proprietary Composite AXL Tumor-Immune Score predicts patients that have significantly prolonged clinical benefit · Primary endpoint of ORR in cohort A met, in predominantly PD-L1 low/negative patients · Combination is 5-fold more active in composite AXL positive patients (33% ORR) vs AXL negative patients (7% ORR) · Secondary endpoint, median Progression Free Survival of 8.4 months in composite AXL score positive patients, exceeds expectations, 3-fold longer than for composite AXL negative patients. Bergen, Norway, 8 November 2019 – BerGenBio ASA (OSE:BGBIO), a